List of Tables
Table 1. Global Physiologically Active Peptides Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Physiologically Active Peptides Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Physiologically Active Peptides Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Physiologically Active Peptides Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Physiologically Active Peptides Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Physiologically Active Peptides Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Tons)
Table 7. Global Physiologically Active Peptides Sales by Region (2020-2025) & (Tons)
Table 8. Global Physiologically Active Peptides Sales by Region (2026-2031) & (Tons)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Physiologically Active Peptides Production Growth Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Tons)
Table 11. Global Physiologically Active Peptides Production by Region (2020-2025) & (Tons)
Table 12. Global Physiologically Active Peptides Production by Region (2026-2031) & (Tons)
Table 13. Global Physiologically Active Peptides Sales by Manufacturers (2020-2025) & (Tons)
Table 14. Global Physiologically Active Peptides Sales Share by Manufacturers (2020-2025)
Table 15. Global Physiologically Active Peptides Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 16. Global Physiologically Active Peptides Revenue Market Share by Manufacturers (2020-2025)
Table 17. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 18. Global Physiologically Active Peptides by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Physiologically Active Peptides as of 2024)
Table 19. Global Physiologically Active Peptides Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 20. Global Physiologically Active Peptides Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Ton)
Table 21. Key Manufacturers Physiologically Active Peptides Manufacturing Base and Headquarters
Table 22. Global Physiologically Active Peptides Market Concentration Ratio (CR5 and HHI)
Table 23. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 24. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 25. Global Physiologically Active Peptides Sales by Type (2020-2025) & (Tons)
Table 26. Global Physiologically Active Peptides Sales by Type (2026-2031) & (Tons)
Table 27. Global Physiologically Active Peptides Revenue by Type (2020-2025) & (US$ Million)
Table 28. Global Physiologically Active Peptides Revenue by Type (2026-2031) & (US$ Million)
Table 29. Global Physiologically Active Peptides ASP by Type (2020-2031) & (US$/Ton)
Table 30. Technical Specifications by Key Product Type
Table 31. Global Physiologically Active Peptides Sales by Application (2020-2025) & (Tons)
Table 32. Global Physiologically Active Peptides Sales by Application (2026-2031) & (Tons)
Table 33. Physiologically Active Peptides High-Growth Sectors Demand CAGR (2024-2031)
Table 34. Global Physiologically Active Peptides Revenue by Application (2020-2025) & (US$ Million)
Table 35. Global Physiologically Active Peptides Revenue by Application (2026-2031) & (US$ Million)
Table 36. Global Physiologically Active Peptides ASP by Application (2020-2031) & (US$/Ton)
Table 37. Top Customers by Region
Table 38. Top Customers by Application
Table 39. North America Physiologically Active Peptides Growth Accelerators and Market Barriers
Table 40. North America Physiologically Active Peptides Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 41. North America Physiologically Active Peptides Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 42. Europe Physiologically Active Peptides Growth Accelerators and Market Barriers
Table 43. Europe Physiologically Active Peptides Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 44. Europe Physiologically Active Peptides Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 45. Asia-Pacific Physiologically Active Peptides Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Asia-Pacific Physiologically Active Peptides Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 47. Asia-Pacific Physiologically Active Peptides Growth Accelerators and Market Barriers
Table 48. Southeast Asia Physiologically Active Peptides Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 49. Central and South America Physiologically Active Peptides Investment Opportunities and Key Challenges
Table 50. Central and South America Physiologically Active Peptides Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 51. Middle East and Africa Physiologically Active Peptides Investment Opportunities and Key Challenges
Table 52. Middle East and Africa Physiologically Active Peptides Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 53. American Peptide Company Inc. Corporation Information
Table 54. American Peptide Company Inc. Description and Major Businesses
Table 55. American Peptide Company Inc. Product Models, Descriptions and Specifications
Table 56. American Peptide Company Inc. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 57. American Peptide Company Inc. Sales Value Proportion by Product in 2024
Table 58. American Peptide Company Inc. Sales Value Proportion by Application in 2024
Table 59. American Peptide Company Inc. Sales Value Proportion by Geographic Area in 2024
Table 60. American Peptide Company Inc. Physiologically Active Peptides SWOT Analysis
Table 61. American Peptide Company Inc. Recent Developments
Table 62. Phermpep Co. Ltd. Corporation Information
Table 63. Phermpep Co. Ltd. Description and Major Businesses
Table 64. Phermpep Co. Ltd. Product Models, Descriptions and Specifications
Table 65. Phermpep Co. Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 66. Phermpep Co. Ltd. Sales Value Proportion by Product in 2024
Table 67. Phermpep Co. Ltd. Sales Value Proportion by Application in 2024
Table 68. Phermpep Co. Ltd. Sales Value Proportion by Geographic Area in 2024
Table 69. Phermpep Co. Ltd. Physiologically Active Peptides SWOT Analysis
Table 70. Phermpep Co. Ltd. Recent Developments
Table 71. ALEXIS Corporation Corporation Information
Table 72. ALEXIS Corporation Description and Major Businesses
Table 73. ALEXIS Corporation Product Models, Descriptions and Specifications
Table 74. ALEXIS Corporation Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 75. ALEXIS Corporation Sales Value Proportion by Product in 2024
Table 76. ALEXIS Corporation Sales Value Proportion by Application in 2024
Table 77. ALEXIS Corporation Sales Value Proportion by Geographic Area in 2024
Table 78. ALEXIS Corporation Physiologically Active Peptides SWOT Analysis
Table 79. ALEXIS Corporation Recent Developments
Table 80. Merck KGaA Corporation Information
Table 81. Merck KGaA Description and Major Businesses
Table 82. Merck KGaA Product Models, Descriptions and Specifications
Table 83. Merck KGaA Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 84. Merck KGaA Sales Value Proportion by Product in 2024
Table 85. Merck KGaA Sales Value Proportion by Application in 2024
Table 86. Merck KGaA Sales Value Proportion by Geographic Area in 2024
Table 87. Merck KGaA Physiologically Active Peptides SWOT Analysis
Table 88. Merck KGaA Recent Developments
Table 89. Promega Corporation Corporation Information
Table 90. Promega Corporation Description and Major Businesses
Table 91. Promega Corporation Product Models, Descriptions and Specifications
Table 92. Promega Corporation Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 93. Promega Corporation Sales Value Proportion by Product in 2024
Table 94. Promega Corporation Sales Value Proportion by Application in 2024
Table 95. Promega Corporation Sales Value Proportion by Geographic Area in 2024
Table 96. Promega Corporation Physiologically Active Peptides SWOT Analysis
Table 97. Promega Corporation Recent Developments
Table 98. Advanced Bioconcept Company Corporation Information
Table 99. Advanced Bioconcept Company Description and Major Businesses
Table 100. Advanced Bioconcept Company Product Models, Descriptions and Specifications
Table 101. Advanced Bioconcept Company Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 102. Advanced Bioconcept Company Recent Developments
Table 103. Arlak Biotech Corporation Information
Table 104. Arlak Biotech Description and Major Businesses
Table 105. Arlak Biotech Product Models, Descriptions and Specifications
Table 106. Arlak Biotech Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 107. Arlak Biotech Recent Developments
Table 108. WN Pharmaceuticals Ltd. Corporation Information
Table 109. WN Pharmaceuticals Ltd. Description and Major Businesses
Table 110. WN Pharmaceuticals Ltd. Product Models, Descriptions and Specifications
Table 111. WN Pharmaceuticals Ltd. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 112. WN Pharmaceuticals Ltd. Recent Developments
Table 113. Anaspec Inc. Corporation Information
Table 114. Anaspec Inc. Description and Major Businesses
Table 115. Anaspec Inc. Product Models, Descriptions and Specifications
Table 116. Anaspec Inc. Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 117. Anaspec Inc. Recent Developments
Table 118. Thermo Fisher Scientific Corporation Information
Table 119. Thermo Fisher Scientific Description and Major Businesses
Table 120. Thermo Fisher Scientific Product Models, Descriptions and Specifications
Table 121. Thermo Fisher Scientific Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 122. Thermo Fisher Scientific Recent Developments
Table 123. Seagarden AS Corporation Information
Table 124. Seagarden AS Description and Major Businesses
Table 125. Seagarden AS Product Models, Descriptions and Specifications
Table 126. Seagarden AS Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 127. Seagarden AS Recent Developments
Table 128. Novo Nordisk A/S Corporation Information
Table 129. Novo Nordisk A/S Description and Major Businesses
Table 130. Novo Nordisk A/S Product Models, Descriptions and Specifications
Table 131. Novo Nordisk A/S Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 132. Novo Nordisk A/S Recent Developments
Table 133. Key Raw Materials Distribution
Table 134. Raw Materials Key Suppliers
Table 135. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 136. Milestones in Production Technology Evolution
Table 137. Distributors List
Table 138. Market Trends and Market Evolution
Table 139. Market Drivers and Opportunities
Table 140. Market Challenges, Risks, and Restraints
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
List of Figures
Figure 1. Physiologically Active Peptides Product Picture
Figure 2. Global Physiologically Active Peptides Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Antimicrobial Peptides Product Picture
Figure 4. Neuroactive Peptides Product Picture
Figure 5. Immunoactive Peptides Product Picture
Figure 6. Antioxidant Peptides Product Picture
Figure 7. Others Product Picture
Figure 8. Global Physiologically Active Peptides Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Food and Beverages
Figure 10. Cosmetics
Figure 11. Others
Figure 12. Physiologically Active Peptides Report Years Considered
Figure 13. Global Physiologically Active Peptides Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Physiologically Active Peptides Revenue (2020-2031) & (US$ Million)
Figure 15. Global Physiologically Active Peptides Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global Physiologically Active Peptides Revenue Market Share by Region (2020-2031)
Figure 17. Global Physiologically Active Peptides Sales (2020-2031) & (Tons)
Figure 18. Global Physiologically Active Peptides Sales (CAGR) by Region (2020-2031) (Tons)
Figure 19. Global Physiologically Active Peptides Sales Market Share by Region (2020-2031)
Figure 20. Global Physiologically Active Peptides Capacity, Production and Utilization (2020-2031) & (Tons)
Figure 21. Global Physiologically Active Peptides Production Trend by Region (2020-2031) (Tons)
Figure 22. Global Physiologically Active Peptides Production Market Share by Region (2020-2031)
Figure 23. Production Capacity Enablers & Constraints
Figure 24. Physiologically Active Peptides Production Growth Rate in North America (2020-2031) & (Tons)
Figure 25. Physiologically Active Peptides Production Growth Rate in Europe (2020-2031) & (Tons)
Figure 26. Physiologically Active Peptides Production Growth Rate in China (2020-2031) & (Tons)
Figure 27. Physiologically Active Peptides Production Growth Rate in Japan (2020-2031) & (Tons)
Figure 28. Top 5 and Top 10 Manufacturers Physiologically Active Peptides Sales Volume Market Share in 2024
Figure 29. Global Physiologically Active Peptides Revenue Market Share Ranking (2024)
Figure 30. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 31. Antimicrobial Peptides Revenue Market Share by Manufacturer in 2024
Figure 32. Neuroactive Peptides Revenue Market Share by Manufacturer in 2024
Figure 33. Immunoactive Peptides Revenue Market Share by Manufacturer in 2024
Figure 34. Antioxidant Peptides Revenue Market Share by Manufacturer in 2024
Figure 35. Others Revenue Market Share by Manufacturer in 2024
Figure 36. Type Eight Revenue Market Share by Manufacturer in 2024
Figure 37. Type Nine Revenue Market Share by Manufacturer in 2024
Figure 38. Global Physiologically Active Peptides Sales Market Share by Type (2020-2031)
Figure 39. Global Physiologically Active Peptides Revenue Market Share by Type (2020-2031)
Figure 40. Global Physiologically Active Peptides Sales Market Share by Application (2020-2031)
Figure 41. Global Physiologically Active Peptides Revenue Market Share by Application (2020-2031)
Figure 42. North America Physiologically Active Peptides Sales YoY (2020-2031) & (Tons)
Figure 43. North America Physiologically Active Peptides Revenue YoY (2020-2031) & (US$ Million)
Figure 44. North America Top 5 Manufacturers Physiologically Active Peptides Sales Revenue (US$ Million) in 2024
Figure 45. North America Physiologically Active Peptides Sales Volume (Tons) by Type (2020- 2031)
Figure 46. North America Physiologically Active Peptides Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 47. North America Physiologically Active Peptides Sales Volume (Tons) by Application (2020-2031)
Figure 48. North America Physiologically Active Peptides Sales Revenue (US$ Million) by Application (2020-2031)
Figure 49. US Physiologically Active Peptides Revenue (2020-2031) & (US$ Million)
Figure 50. Canada Physiologically Active Peptides Revenue (2020-2031) & (US$ Million)
Figure 51. Mexico Physiologically Active Peptides Revenue (2020-2031) & (US$ Million)
Figure 52. Europe Physiologically Active Peptides Sales YoY (2020-2031) & (Tons)
Figure 53. Europe Physiologically Active Peptides Revenue YoY (2020-2031) & (US$ Million)
Figure 54. Europe Top 5 Manufacturers Physiologically Active Peptides Sales Revenue (US$ Million) in 2024
Figure 55. Europe Physiologically Active Peptides Sales Volume (Tons) by Type (2020-2031)
Figure 56. Europe Physiologically Active Peptides Sales Revenue (US$ Million) by Type (2020-2031)
Figure 57. Europe Physiologically Active Peptides Sales Volume (Tons) by Application (2020-2031)
Figure 58. Europe Physiologically Active Peptides Sales Revenue (US$ Million) by Application (2020-2031)
Figure 59. Germany Physiologically Active Peptides Revenue (2020-2031) & (US$ Million)
Figure 60. France Physiologically Active Peptides Revenue (2020-2031) & (US$ Million)
Figure 61. U.K. Physiologically Active Peptides Revenue (2020-2031) & (US$ Million)
Figure 62. Italy Physiologically Active Peptides Revenue (2020-2031) & (US$ Million)
Figure 63. Russia Physiologically Active Peptides Revenue (2020-2031) & (US$ Million)
Figure 64. Asia-Pacific Physiologically Active Peptides Sales YoY (2020-2031) & (Tons)
Figure 65. Asia-Pacific Physiologically Active Peptides Revenue YoY (2020-2031) & (US$ Million)
Figure 66. Asia-Pacific Top 8 Manufacturers Physiologically Active Peptides Sales Revenue (US$ Million) in 2024
Figure 67. Asia-Pacific Physiologically Active Peptides Sales Volume (Tons) by Type (2020- 2031)
Figure 68. Asia-Pacific Physiologically Active Peptides Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 69. Asia-Pacific Physiologically Active Peptides Sales Volume (Tons) by Application (2020-2031)
Figure 70. Asia-Pacific Physiologically Active Peptides Sales Revenue (US$ Million) by Application (2020-2031)
Figure 71. Indonesia Physiologically Active Peptides Revenue (2020-2031) & (US$ Million)
Figure 72. Japan Physiologically Active Peptides Revenue (2020-2031) & (US$ Million)
Figure 73. South Korea Physiologically Active Peptides Revenue (2020-2031) & (US$ Million)
Figure 74. China Taiwan Physiologically Active Peptides Revenue (2020-2031) & (US$ Million)
Figure 75. India Physiologically Active Peptides Revenue (2020-2031) & (US$ Million)
Figure 76. Central and South America Physiologically Active Peptides Sales YoY (2020-2031) & (Tons)
Figure 77. Central and South America Physiologically Active Peptides Revenue YoY (2020-2031) & (US$ Million)
Figure 78. Central and South America Top 5 Manufacturers Physiologically Active Peptides Sales Revenue (US$ Million) in 2024
Figure 79. Central and South America Physiologically Active Peptides Sales Volume (Tons) by Type (2021-2031)
Figure 80. Central and South America Physiologically Active Peptides Sales Revenue (US$ Million) by Type (2020-2031)
Figure 81. Central and South America Physiologically Active Peptides Sales Volume (Tons) by Application (2020-2031)
Figure 82. Central and South America Physiologically Active Peptides Sales Revenue (US$ Million) by Application (2020-2031)
Figure 83. Brazil Physiologically Active Peptides Revenue (2020-2025) & (US$ Million)
Figure 84. Argentina Physiologically Active Peptides Revenue (2020-2025) & (US$ Million)
Figure 85. Middle East, and Africa Physiologically Active Peptides Sales YoY (2020-2031) & (Tons)
Figure 86. Middle East and Africa Physiologically Active Peptides Revenue YoY (2020-2031) & (US$ Million)
Figure 87. Middle East and Africa Top 5 Manufacturers Physiologically Active Peptides Sales Revenue (US$ Million) in 2024
Figure 88. Middle East and Africa Physiologically Active Peptides Sales Volume (Tons) by Type (2021-2031)
Figure 89. South America Physiologically Active Peptides Sales Revenue (US$ Million) by Type (2020-2031)
Figure 90. Middle East and Africa Physiologically Active Peptides Sales Volume (Tons) by Application (2020-2031)
Figure 91. Middle East and Africa Physiologically Active Peptides Sales Revenue (US$ Million) by Application (2020-2031)
Figure 92. GCC Countries Physiologically Active Peptides Revenue (2020-2025) & (US$ Million)
Figure 93. Turkey Physiologically Active Peptides Revenue (2020-2025) & (US$ Million)
Figure 94. Egypt Physiologically Active Peptides Revenue (2020-2025) & (US$ Million)
Figure 95. South Africa Physiologically Active Peptides Revenue (2020-2025) & (US$ Million)
Figure 96. Physiologically Active Peptides Industry Chain Mapping
Figure 97. Regional Physiologically Active Peptides Manufacturing Base Distribution (%)
Figure 98. Physiologically Active Peptides Production Process
Figure 99. Regional Physiologically Active Peptides Production Cost Structure
Figure 100. Channels of Distribution (Direct Vs Distribution)
Figure 101. Bottom-up and Top-down Approaches for This Report
Figure 102. Data Triangulation
Figure 103. Key Executives Interviewed
